Asthma And COPD Drugs Market To Grow From USD 33.16 Billion In 2025 To USD 56.21 Billion By 2035, At A CAGR Of 5.42% - SNS Insider
Austin, United States, Sept. 03, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Asthma and COPD Drugs Market
Combination inhalers with both corticosteroids and bronchodilators, biologics that target inflammation, and digital inhalers that provide real-time tracking information play a key role in advancing respiratory treatment through modernizing the field with increased investment in personalized medicine.
Asthma and COPD Drugs Market Key Highlights
- Market size, 2025: USD 33.16 Billion Market forecast, 2035: USD 56.21 Billion CAGR: 5.42% from 2026 to 2035 Largest region: North America, approximately 36.58% share in 2025 Fastest-growing region: Asia-Pacific, approximately 5.96% CAGR Largest drug type: Bronchodilators, approximately 44.80% share in 2025 Fastest-growing drug type: Combined therapies, approximately 10.60% CAGR Largest prescription type: Prescription (Rx) drugs, approximately 71.25% share in 2025 Fastest-growing prescription type: Over-the-counter (OTC) drugs, approximately 9.20% CAGR Largest disease type: COPD, approximately 58.40% share in 2025 Fastest-growing disease type: Asthma, approximately 8.90% CAGR Largest distribution channel: Retail pharmacies, approximately 48.75% share in 2025 Fastest-growing distribution channel: Online pharmacies, approximately 11.10% CAGR
Market Relevance
The treatment of respiratory diseases has now become an essential component of healthcare services with COPD being reported to be the third leading cause of mortality by the WHO, resulting in about 3.2 million deaths per year. Both asthma and COPD affect more than 600 million people globally in 2025.
Asthma and COPD Drugs Market Overview
The market includes bronchodilators, corticosteroid-bronchodilator combination drugs, and biologics available through retail pharmacies and online pharmacies as prescription and over-the-counter drugs. Bronchodilators continue to be pivotal for the instant relief of symptoms in both asthma and COPD patients, whereas combination inhalers that include corticosteroids and bronchodilators have become popular choices for managing diseases in the long run. There has been a rise in the use of digital or smart inhalers that help track the dosage taken, and more than 40% of inhalers prescribed in the United States and Europe include digital inhalers in 2025.
Strategic Market Outlook
Opportunities for growth include smart inhalers and respiratory medications utilizing biologics, wherein the former provides dose and adherence tracking, presenting new opportunities for drug manufacturers, and the latter involves therapies acting on specific inflammatory pathways to provide personalized treatment options for severe asthma and COPD patients.
Patent expirations and costly biologic treatments continue to be significant roadblocks. The expiration of the patents of branded respiratory medication has increased the number of generics competing in the market, leading to losses for the market leaders, and biologic treatment options have been very costly and unaffordable for patients in developing countries.
Asthma and COPD Drugs Market Regional Analysis
North America held approximately 36.58% of the global market in 2025, making it the largest region, supported by high disease prevalence, advanced healthcare systems, and a strong presence of key pharmaceutical players including GSK, AstraZeneca, and Pfizer, with widespread use of biologics, digital inhalers, and combination therapies, favorable reimbursement structures, and ongoing FDA approvals for innovative respiratory treatments.
The U.S . Asthma and COPD Drugs Market was valued at USD 8.56 Billion in 2025 and is projected to reach USD 14.04 Billion by 2035, growing at a CAGR of 5.07% from 2026 to 2035, driven by high patient awareness, robust healthcare infrastructure, and strong R&D activity.
The Europe Asthma and COPD Drugs Market was valued at USD 9.62 Billion in 2025 and is projected to reach USD 15.97 Billion by 2035, growing at a CAGR of 5.20% from 2026 to 2035, with the U.K., France, and Italy showing high drug uptake, supported by regulatory backing for biosimilars, rising pollution, and aging populations.
The Asia-Pacific region is expected to witness the fastest growth, with a projected CAGR of approximately 5.96% from 2026 to 2035, driven by increasing pollution levels, smoking rates, and urbanization, with governments across India, Japan, and South Korea enhancing respiratory healthcare programs and an expanding elderly population further driving treatment demand.
Buy the Asthma and COPD Drugs Market Report with Competitive Analysis and 2035 Forecast:Asthma and COPD Drugs Market Segment Analysis
By Drug Type: The bronchodilators had a market share of about 44.80% in 2025 due to their extensive usage for treating airway obstruction. The segment that is growing at the highest rate is that of combination therapy, growing at about 10.60% CAGR.
By Prescription Type: The prescription drug held a market share of approximately 71.25% due to the prevalence of chronic diseases and need for constant monitoring from a doctor. The over-the-counter segment is witnessing the fastest growth at approximately 9.20% CAGR due to the prevalence of self-medicating practices for respiratory ailments.
By Disease Type: The COPD has approximately 58.40% market share in 2025, given the high prevalence of COPD in the global population. The Asthma has a fast growth rate of about 8.90% CAGR owing to the increasing prevalence of asthma among the young generation.
By Distribution Channel: The retail pharmacy accounted for a market share of approximately 48.75%, representing the major source of sale for both prescription drugs and OTC drugs. The online pharmacy is the fastest-growing sales channel, with a CAGR of approximately 11.10%, fueled by digitization and telemedicine.
Asthma and COPD Drugs Market Key Trends
- Rising demand for combination inhalers integrating corticosteroids and bronchodilators to improve patient adherence Increasing adoption of biologics targeting specific inflammatory pathways in severe asthma and advanced COPD management Growth in digital and smart inhalers offering real-time monitoring and improved patient compliance Expanding R&D investment in next-generation therapies focused on personalized and precision medicine Rising prevalence of asthma and COPD due to urban pollution, aging population, and smoking-related health issues
Competitive Landscape
The Asthma and COPD Drugs Market include established respiratory pharmaceutical leaders with portfolios spanning biologics, combination inhalers, and long-acting bronchodilators.
In March 2024, AstraZeneca partnered with Mankind Pharma in India to expand access to its inhaled corticosteroid-LABA combination therapy. In March 2024, Boehringer Ingelheim launched an out-of-pocket cap initiative limiting inhaler costs to $35 monthly for eligible U.S. patients. In March 2025, GSK received FDA acceptance for Depemokimab, a biologic targeting severe asthma and chronic rhinosinusitis. In July 2025, Novartis secured European Commission approval for Enerzair Breezhaler, a smart inhaler therapy with a digital companion for adults with uncontrolled asthma.
Major key players include
- AstraZeneca PLC Boehringer Ingelheim GmbH GlaxoSmithKline PLC Novartis AG F. Hoffmann-La Roche Ltd Pfizer Inc. Sanofi SA Merck & Co. Inc. Teva Pharmaceutical Industries Ltd Chiesi Farmaceutici SpA Azurity Pharmaceuticals Inc. Grifols SA Viatris Inc. Cipla Ltd Orion Corporation Regeneron Pharmaceuticals Inc. Amgen Inc. Sun Pharmaceutical Industries Limited Theravance Biopharma Inc. Verona Pharma PLC
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment